Document is current
Any future updates will be listed below
-
Authors
Elkind, Mitchell S. V.
Witte, Klaus K.
Kasner, Scott E.
Sawyer, Laura M.
Grimsey Jones, Frank W.
Rinciog, Claudia
Tsintzos, Stelios
Rosemas, Sarah C.
Lanctin, David
Ziegler, Paul D.
Reynolds, Matthew R.
-
Funding
Funding for this research was provided by:
Medtronic
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 16 January 2023
First Online: 25 January 2023
Declarations
:
: No ethics approval or consent to participate was required.
: Not applicable.
: CR, LS and FG are employed by Symmetron Ltd, which received funding from Medtronic for this analysis. KW has received unconditional research funding from Medtronic to the University of Leeds for a Ph.D. Fellowship program and consultancy or speaker fees from Medtronic, Novartis, AstraZeneca, Pfizer, Napp, Abbott, Cardiac Dimensions, Microport. MR has received consultancy fees from Medtronic. SK has received consultancy fees from Medtronic and Bristol-Myers Squibb. ME’s institution received funding for his participation in these analyses, and ME receives study drug in kind but no personal compensation from the BMS-Pfizer Alliance for Eliquis and ancillary research funding from Roche, both for a National Institutes of Health-funded trial of stroke prevention in patients with atrial cardiopathy. SR, PZ, DL, and ST are Medtronic employees. The REVEAL AF study and this cost-effectiveness analysis were funded by Medtronic.
